Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.

Date
2021
Author
Turk, Haci M.
Rietschel, Petra
Bentsion, Dmitry
Cicin, Irfan
Gogishvili, Miranda
Gullo, Giuseppe
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Lowy, Israel
Seebach, Frank A.
Lee, Sue
Pouliot, Jean-Francois
McGinniss, Jennifer
Rizvi, Naiyer A.
Sriuranpong, Virote
Clingan, Philip R.
Gladkov, Oleg
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/168557
https://doi.org/10.1200/jco.2021.39.15_suppl.9085
Collections